Small-molecule control of antibody N-glycosylation in engineered mammalian cells
N-linked glycosylation in monoclonal antibodies (mAbs) is crucial for structural and functional properties of mAb therapeutics, including stability, pharmacokinetics, safety and clinical efficacy. The biopharmaceutical industry currently lacks tools to precisely control N-glycosylation levels during...
Autors principals: | , , , , , , , , , , , , , , , , , , , |
---|---|
Altres autors: | |
Format: | Article |
Idioma: | English |
Publicat: |
Springer Science and Business Media LLC
2020
|
Accés en línia: | https://hdl.handle.net/1721.1/125977 |